NEW YORK, Jan. 31, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKT:PXRB) and certain of its officers, on behalf of a class who purchased PixarBio securities: (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pxrb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s statements in press releases, third-party promotional materials, and its Form S-1 regarding, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and its current and prospective development efforts lacked accuracy; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
On January 23, 2017, the SEC disclosed the temporary suspension of PixarBio trading “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.”
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pxrb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Britain Courts Anthropic Amid US Defense Department Dispute
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 



